UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Volumetric PET Response Assessment Outperforms Conventional Criteria in Patients Receiving High-Dose Pembrolizumab for Malignant Mesothelioma

Journal of Nuclear Medicine, 2021-02, Vol.62 (2), p.191-194

2021

Volltextzugriff (PDF)

Gene expression profiling of homologous recombination repair pathway indicates susceptibility for olaparib treatment in malignant pleural mesothelioma in vitro

BMC cancer, 2019-01, Vol.19 (1), p.108-12, Article 108

2019

Volltextzugriff (PDF)

Lorlatinib in pretreated ALK- or ROS1-positive lung cancer and impact of TP53 co-mutations: results from the German early access program

Therapeutic advances in medical oncology, 2021, Vol.13, p.1758835920980558-1758835920980558

2021

Volltextzugriff (PDF)

Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study

Journal of thoracic oncology, 2023-02, Vol.18 (2), p.181-193

2023

Volltextzugriff (PDF)

Clinical Experience of Immunotherapy Treatment: Efficacy and Toxicity Analysis of the Compassionate Use Program of Nivolumab in Patients with Advanced Squamous Cell Non-Small Cell Lung Cancer

Oncology research and treatment, 2019-01, Vol.42 (5), p.243-255

2019

Volltextzugriff (PDF)

Durvalumab after definitive chemoradiotherapy in locally advanced NSCLC: Data of the German EAP

Data in brief, 2021-02, Vol.34, p.106556-106556, Article 106556

2021

Volltextzugriff (PDF)

Pulmonary Adenocarcinoma with Enteric Differentiation without TTF-1 Expression Is a Very Rare Subtype with Limited Treatment Options and Poor Prognosis

Oncology, 2024-08, p.1-13

2024

Volltextzugriff (PDF)

Thymidylate Synthase Protein Expression by IHC and Gene Copy Number by SISH Correlate and Show Great Variability in Non–Small Cell Lung Cancer

Journal of thoracic oncology, 2012-06, Vol.7 (6), p.982-992

2012

Volltextzugriff (PDF)

CONTACT-01: A Randomized Phase III Trial of Atezolizumab + Cabozantinib Versus Docetaxel for Metastatic Non-Small Cell Lung Cancer After a Checkpoint Inhibitor and Chemotherapy

Journal of clinical oncology, 2024-07, Vol.42 (20), p.2393-2403

2024

Volltextzugriff (PDF)

Activation of angiogenesis differs strongly between pulmonary carcinoids and neuroendocrine carinomas and is crucial for carcinoid tumourgenesis

Journal of Cancer, 2014-01, Vol.5 (6), p.465-471

2014

Volltextzugriff (PDF)

High Prevalence of Concomitant Oncogene Mutations in Prospectively Identified Patients with ROS1-Positive Metastatic Lung Cancer

Journal of thoracic oncology, 2017-01, Vol.12 (1), p.54-64

2017

Volltextzugriff (PDF)

Everolimus after failure of one prior VEGF‐targeted therapy in metastatic renal cell carcinoma: Final results of the MARC‐2 trial

International journal of cancer, 2021-04, Vol.148 (7), p.1685-1694

2021

Volltextzugriff (PDF)

Significance of Folate Receptor Alpha and Thymidylate Synthase Protein Expression in Patients with Non–Small-Cell Lung Cancer Treated with Pemetrexed

Journal of thoracic oncology, 2013-01, Vol.8 (1), p.19-30

2013

Volltextzugriff (PDF)

Real-world efficacy of docetaxel plus nintedanib after chemo-immunotherapy failure in advanced pulmonary adenocarcinoma

Future oncology (London, England), 2021-10, Vol.17 (30), p.3965-3976

2021

Volltextzugriff (PDF)

Systemic treatment of malignant pleural mesothelioma: new agents in clinical trials raise hope of relevant improvements

Current opinion in oncology, 2014-03, Vol.26 (2), p.171-181

2014

Volltextzugriff (PDF)

Efficacy and safety of nivolumab combined with standard therapies for first-line therapy of advanced non-small cell lung cancer

Journal of thoracic disease, 2016-10, Vol.8 (10), p.E1254-E1256

2016

Volltextzugriff (PDF)

Efficacy and safety analysis of the German expanded access program of osimertinib in patients with advanced, T790M-positive non-small cell lung cancer

Journal of cancer research and clinical oncology, 2018-12, Vol.144 (12), p.2457-2463

2018

Volltextzugriff (PDF)

Polo-like kinase 1 inhibitors in mono- and combination therapies: a new strategy for treating malignancies

Expert review of anticancer therapy, 2011-07, Vol.11 (7), p.1117-1132

2011

Volltextzugriff (PDF)

NSCLC: Neoadjuvante oder adjuvante Therapie: Wohin geht die Reise bei lokal fortgeschrittenen Tumoren?

Im Fokus Onkologie, 2023-07, Vol.26 (3), p.13-17

2023

Volltextzugriff (PDF)

Digital Gene Expression Analysis of Epithelioid and Sarcomatoid Mesothelioma Reveals Differences in Immunogenicity

Cancers, 2021-04, Vol.13 (8), p.1761

2021

Volltextzugriff (PDF)

A nomogram to predict the recurrence-free survival and analyze the utility of chemotherapy in stage IB non-small cell lung cancer

Translational lung cancer research, 2022-01, Vol.11 (1), p.75-86

2022

Volltextzugriff (PDF)

Intraventricular Chemotherapy for Leptomeningeal Carcinomatosis from Lung Cancer: A Feasible and Beneficial Treatment Option?

Journal of thoracic oncology, 2013-05, Vol.8 (5), p.523-524

2013

Volltextzugriff (PDF)

Immunohistochemically detectable metallothionein expression in malignant pleural mesotheliomas is strongly associated with early failure to platin-based chemotherapy

Oncotarget, 2018-04, Vol.9 (32), p.22254-22268

2018

Volltextzugriff (PDF)

First-line treatment selection with organoids of an EGFRm + TP53m stage IA1 patient with early metastatic recurrence after radical surgery and follow-up

Journal of thoracic disease, 2020-07, Vol.12 (7), p.3764-3773

2020

Volltextzugriff (PDF)

Rapid and Highly Sensitive Detection of Therapeutically Relevant Oncogenic Driver Mutations in EBUS-TBNA Specimens From Patients With Lung Adenocarcinoma

Clinical lung cancer, 2018-11, Vol.19 (6), p.e879-e884

2018

Volltextzugriff (PDF)

1 – 25 von 2.427

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(2.082)
Mit Volltextzugriff
(2.060)

Publikationsform

Artikel
(1.966)
Tagungsberichte
(202)
Buchkapitel
(173)
Bücher
(80)
Berichte
(4)
Reviews
(2)

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Englisch
(2.266)
Deutsch
(90)
Französisch
(76)
Japanisch
(2)
Spanisch
(2)
Russisch
(1)

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(1.807)
Life Sciences & Biomedicine
(1.208)
Humans
(864)
Male
(442)
Female
(425)
Technology
(358)
Physical Sciences
(279)
Adult
(255)
Biological And Medical Sciences
(255)
Animals
(250)
Middle Aged
(242)
Aged
(228)
Computer Science
(173)
Medical Sciences
(151)
Neurosciences & Neurology
(124)
Cardiovascular System & Cardiology
(109)
Biochemistry & Molecular Biology
(106)
Science & Technology - Other Topics
(102)
Computer Science, Theory & Methods
(98)
Applied Sciences
(93)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Nature
(36)
The New England Journal Of Medicine
(32)
Cancer Research
(26)
Nature Communications
(24)
Blood
(22)
Plos One
(20)
Proceedings Of The National Academy Of Sciences - Pnas
(20)
Scientific Reports
(20)
Circulation
(19)
Atmospheric Chemistry And Physics
(17)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(32)
... seit 30 Tagen
(12)

Menü

Weitere Dienste

Einstellungen

Volumetric PET Response Assessment Outperforms Conventional Criteria in Patients Receiving High-Dose Pembrolizumab for Malignant Mesothelioma

Gene expression profiling of homologous recombination repair pathway indicates susceptibility for olaparib treatment in malignant pleural mesothelioma in vitro

Lorlatinib in pretreated ALK- or ROS1-positive lung cancer and impact of TP53 co-mutations: results from the German early access program

Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study

Clinical Experience of Immunotherapy Treatment: Efficacy and Toxicity Analysis of the Compassionate Use Program of Nivolumab in Patients with Advanced Squamous Cell Non-Small Cell Lung Cancer

Durvalumab after definitive chemoradiotherapy in locally advanced NSCLC: Data of the German EAP

Pulmonary Adenocarcinoma with Enteric Differentiation without TTF-1 Expression Is a Very Rare Subtype with Limited Treatment Options and Poor Prognosis

Thymidylate Synthase Protein Expression by IHC and Gene Copy Number by SISH Correlate and Show Great Variability in Non–Small Cell Lung Cancer

CONTACT-01: A Randomized Phase III Trial of Atezolizumab + Cabozantinib Versus Docetaxel for Metastatic Non-Small Cell Lung Cancer After a Checkpoint Inhibitor and Chemotherapy

Activation of angiogenesis differs strongly between pulmonary carcinoids and neuroendocrine carinomas and is crucial for carcinoid tumourgenesis

High Prevalence of Concomitant Oncogene Mutations in Prospectively Identified Patients with ROS1-Positive Metastatic Lung Cancer

Everolimus after failure of one prior VEGF‐targeted therapy in metastatic renal cell carcinoma: Final results of the MARC‐2 trial

Significance of Folate Receptor Alpha and Thymidylate Synthase Protein Expression in Patients with Non–Small-Cell Lung Cancer Treated with Pemetrexed

Real-world efficacy of docetaxel plus nintedanib after chemo-immunotherapy failure in advanced pulmonary adenocarcinoma

Systemic treatment of malignant pleural mesothelioma: new agents in clinical trials raise hope of relevant improvements

Efficacy and safety of nivolumab combined with standard therapies for first-line therapy of advanced non-small cell lung cancer

Efficacy and safety analysis of the German expanded access program of osimertinib in patients with advanced, T790M-positive non-small cell lung cancer

Polo-like kinase 1 inhibitors in mono- and combination therapies: a new strategy for treating malignancies

NSCLC: Neoadjuvante oder adjuvante Therapie: Wohin geht die Reise bei lokal fortgeschrittenen Tumoren?

Digital Gene Expression Analysis of Epithelioid and Sarcomatoid Mesothelioma Reveals Differences in Immunogenicity

A nomogram to predict the recurrence-free survival and analyze the utility of chemotherapy in stage IB non-small cell lung cancer

Intraventricular Chemotherapy for Leptomeningeal Carcinomatosis from Lung Cancer: A Feasible and Beneficial Treatment Option?

Immunohistochemically detectable metallothionein expression in malignant pleural mesotheliomas is strongly associated with early failure to platin-based chemotherapy

First-line treatment selection with organoids of an EGFRm + TP53m stage IA1 patient with early metastatic recurrence after radical surgery and follow-up

Rapid and Highly Sensitive Detection of Therapeutically Relevant Oncogenic Driver Mutations in EBUS-TBNA Specimens From Patients With Lung Adenocarcinoma

Suchergebnisse filtern